Effect of noradrenergic drugs explored in Alzheimer’s disease
Jul 29, 2022
Meta-analyses suggest positive effects of noradrenergic drugs on global cognition and apathy.
Instrumental activities of daily living test could ID Alzheimer’s disease
Jun 28, 2023
An association was found between simulated real-life IADL and interactions of amyloid and early tau accumulation in cognitively normal seniors.
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Hypertension, type 2 diabetes contribute to brain changes in Puerto Rican seniors
Apr 01, 2022
A high prevalence of hypertension and type 2 diabetes was seen among the Puerto Rican cohort; those with both have deteriorating patterns in major white matter tracts.
Neuroimaging measures linked to stages of memory impairment
Mar 04, 2022
The presence of Alzheimer’s disease pathology is related to Stages of Objective Memory Impairment in cognitively unimpaired older adults.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Racial/ethnic minorities underrepresented in Alzheimer’s neuroimaging research
Jul 28, 2023
Sample diversity has improved recently, with proportion of Blacks increasing from 3.39% in 1994-2017 to 8.29% in 2018-2022.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.